| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $64.0M | +39.0% |
| SG&A Expense | $25.2M | +19.6% |
| Operating Income | -$89.2M | -32.9% |
| Net Income | -$80.6M | -33.4% |
| EPS (Basic) | -$2.38 | +13.1% |
| EPS (Diluted) | -$2.38 | +13.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $39.8M | +10.6% |
| Short-term Investments | $139.7M | +52.7% |
| Current Assets | $181.6M | +40.0% |
| Total Assets | $196.6M | +42.2% |
| Current Liabilities | $17.2M | +29.4% |
| Total Liabilities | $19.8M | +16.0% |
| Stockholders' Equity | $176.8M | +45.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$65.7M | -54.0% |
| Capital Expenditures | $2.8M | +114.9% |
| Investing Cash Flow | -$51.8M | -202.1% |
| Financing Cash Flow | $121.0M | +7888.1% |
| Free Cash Flow | -$68.4M | -55.8% |